Pharmacopsychiatry
DOI: 10.1055/s-0043-112345
Review
© Georg Thieme Verlag KG Stuttgart · New York

Validation of Brain Angiotensin System Blockade as a Novel Drug Target in Pharmacological Treatment of Neuropsychiatric Disorders

Dominik Wincewicz1, 2, Jan J. Braszko1
  • 1Department of Clinical Pharmacology, Medical University of Bialystok, Bialystok, Poland
  • 2Department of Psychiatry, Medical University of Bialystok, Poland
Further Information

Publication History

received 16 September 2016
revised 08 May 2017

accepted 18 May 2017

Publication Date:
22 June 2017 (eFirst)

Abstract

Retreat in psychiatric drug development results in innovative medication decline that might be at least partially overcome by adjunct therapy. New evidence from clinical studies has shown a possible role for brain Renin-Angiotensin System (RAS) in both affective and psychotic disorders. Simultaneously, rapidly accumulating data from basic studies indicate effectiveness of central RAS blockade in much broader range of neuropsychiatric disease. Recent findings implicate brain RAS, especially Angiotensin II (Ang II), in neural pathophysiology of mental disorders through neuroendocrine modulation and effects on neurotransmitter release, mostly noradrenaline, acetylcholine and dopamine. The potential effects of angiotensin-converting-enzyme (ACE) inhibition and angiotensin type 1 receptor (AT1R) blockade on treatment of mental disorders are a matter of considerable interest. This review describes involvement of brain RAS in pathophysiology of neuropsychiatric disorders and an intriguing possibilities of improvement in pharmacological treatment outcome, where using angiotensin-converting-enzyme inhibitors (ACEI) and Angiotensin Receptor Blockers (ARB), goes beyond blood pressure control.